Cytodyn Inc (CYDY)

[Saltz]

My takeaway from Nader’s comments is a confidence in Emergency IND approval for unmet need. Most likely coming from the S2C half way point (195 patients) based on mortality. It’s not out of the question w the M2M trial but IMO unlikely.

Interesting the Nasdaq uplist could come at the same time as the S2C interim. What a 1-2 punch that would be. I can’t even speculate as to where the SP would land.

All in all there is much reason to believe in the upcoming data from both trials given the data from the 60 EIND patients. If your a believer the current SP is a gift.